Harrow, iOR Partners expand national product supply agreement
Click Here to Manage Email Alerts
Harrow and iOR Partners have expanded their national product supply agreement, according to a press release.
Harrow will provide its entire formulary of compounded ophthalmic products to iOR Partners for the company’s expanding office-based surgery locations across the U.S.
Source: Adobe Stock.
The agreement will allow Harrow’s ophthalmic surgery products, including MKO Melt (midazolam, ketamine HCl, ondansetron), which reduces the use of opioids and needles, to be implemented into office-based procedures.
“iOR Partners assists practices nationwide to make office-based ophthalmic surgery a reality,” Mark L. Baum, chairman and CEO of Harrow, said in the release. “Our mission has always focused on making medications accessible and affordable, and working with iOR Partners, the national leader in this fast-growing area of ophthalmic surgery, represents an important and growing channel for Harrow to meet our mission.”
Read more about
Click Here to Manage Email Alerts